SCHEMBL26986930

SCHEMBL26986930

CNC(=O)c1cncc(O)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.42
HPGD P15428 2/20 0.40
BAZ2B Q9UIF8 1/20 0.38
BRD4 O60885 2/20 0.37
GRM5 P41594 2/20 0.36
RAB9A P51151 3/20 0.36
NPC1 O15118 2/20 0.36
POLB P06746 1/20 0.36
CCNC P24863 3/20 0.35
CDK8 P49336 3/20 0.35
CDC7 O00311 1/20 0.35
DBF4 Q9UBU7 1/20 0.35
GAA P10253 1/20 0.35
SCN10A Q9Y5Y9 3/20 0.35
BUB1 O43683 1/20 0.34
MKNK1 Q9BUB5 1/20 0.34
MKNK2 Q9HBH9 1/20 0.34
SCN2A Q99250 2/20 0.34
SCN1A P35498 1/20 0.34
KCNH2 Q12809 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13097165 0.80 GRM5 (0.54) CNR1HPGDBAZ2BBRD4GRM5
SCHEMBL164543 0.80 CNR1 (0.42) CNR1HPGDBAZ2BBRD4GRM5
SCHEMBL2847725 0.78 GRM5 (0.54) CNR1HPGDBAZ2BBRD4GRM5
SCHEMBL22792229 0.78 CTSA (0.48) CNR1HPGDBAZ2BBRD4GRM5
SCHEMBL13883947 0.78 CNR1 (0.41) CNR1HPGDBAZ2BBRD4GRM5
SCHEMBL27315955 0.77 ALDH1A1 (0.34) MKNK1MKNK2KDM4EALDH1A1TSHR
SCHEMBL1571163 0.76 MRGPRX4 (0.43) POLBGAAKDM4EALDH1A1LMNA
SCHEMBL24609421 0.76 CNR1 (0.43) CNR1HPGDBAZ2BBRD4GRM5
SCHEMBL13086458 0.76 CNR1 (0.40) CNR1HPGDBAZ2BBRD4GRM5
SCHEMBL162262 0.74 HCAR2 (0.46) HPGDPOLBKDM4EALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4551570-A1 NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF Dong-A ST Co., Ltd. (KR) 2025-05-14 EP disclosed
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof DONG-A ST CO., LTD. (KR) 2025-03-04 US disclosed
CN-119403798-A Novel compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof 东亚ST 株式会社 2025-02-07 CN disclosed
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US disclosed
WO-2024009215-A1 NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof EIF2AK4, GCN1, GCGR CNR1 4084/4885HPGD 841/4885BAZ2B 3415/4885
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF EIF2AK4, GCN1, GCGR CNR1 4084/4885HPGD 841/4885BAZ2B 3415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.